Myristoyl-L-carnitine-14,14,14-d3 (chloride)
(Synonyms: CAR 14:0-d3, C14:0 Carnitine-d3, L-Carnitine myristoyl ester-d3, L-Carnitine tetradecanoyl ester-d3, L-Myristoylcarnitine-d3, Tetradecanoyl-L-carnitine-d3, L-Tetradecanoylcarnitine-d3) 目录号 : GC47714
A neuropeptide with diverse biological activities
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Myristoyl-L-carnitine-14,14,14-d3 is intended for use as an internal standard for the quantification of myristoyl-L-carnitine by GC- or LC-MS. Myristoyl-L-carnitine is a naturally occurring long-chain acylcarnitine.1 Plasma levels of myristoyl-L-carnitine are decreased in patients with chronic fatigue syndrome and increased in patients with end-stage renal disease.1,2
1.Reuter, S.E., Evans, A.M., Faull, R.J., et al.Impact of haemodialysis on individual endogenous plasma acylcarnitine concentrations in end-stage renal diseaseAnn. Clin. Biochem.42(Pt 5)387-393(2005) 2.Reuter, S.E., and Evans, A.M.Long-chain acylcarnitine deficiency in patients with chronic fatigue syndrome. Potential involvement of altered carnitine palmitoyltransferase-I activityJ. Intern. Med.270(1)76-84(2011)
| Cas No. | N/A | SDF | |
| 别名 | CAR 14:0-d3, C14:0 Carnitine-d3, L-Carnitine myristoyl ester-d3, L-Carnitine tetradecanoyl ester-d3, L-Myristoylcarnitine-d3, Tetradecanoyl-L-carnitine-d3, L-Tetradecanoylcarnitine-d3 | ||
| Canonical SMILES | OC(C[C@H](C[N+](C)(C)C)OC(CCCCCCCCCCCCC([2H])([2H])[2H])=O)=O.[Cl-] | ||
| 分子式 | C21H39D3NO4.Cl | 分子量 | 411 |
| 溶解度 | DMF: 20 mg/ml,DMSO: 14 mg/ml,Ethanol: 20 mg/ml | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.4331 mL | 12.1655 mL | 24.3309 mL |
| 5 mM | 0.4866 mL | 2.4331 mL | 4.8662 mL |
| 10 mM | 0.2433 mL | 1.2165 mL | 2.4331 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
L-tryptophan L-tryptophanium chloride
Spectrochim Acta A Mol Biomol Spectrosc 2015 Feb 5;136 Pt B:743-50.PMID:25448973DOI:10.1016/j.saa.2014.09.090.
L-tryptophan L-tryptophanium chloride is a new salt with (A⋯A(+)) type dimeric cation. It crystallizes in the monoclinic system (space group P2(1), Z=2). The asymmetric unit contains one zwitterionic L-tryptophan molecule, one L-tryptophanium cation and one chloride anion. The dimeric cation is formed by a O-H⋯O hydrogen bond with the O⋯O distance equal to 2.5556(18) Å. The infrared and Raman spectra of the crystal are studied and compared with the spectra of L-tryptophanium chloride.
The hidden hand of chloride in hypertension
Pflugers Arch 2015 Mar;467(3):595-603.PMID:25619794DOI:10.1007/s00424-015-1690-8.
Among the environmental factors that affect blood pressure, dietary sodium chloride has been studied the most, and there is general consensus that increased sodium chloride intake increases blood pressure. There is accruing evidence that chloride may have a role in blood pressure regulation which may perhaps be even more important than that of Na(+). Though more than 85 % of Na(+) is consumed as sodium chloride, there is evidence that Na(+) and Cl(-) concentrations do not go necessarily hand in hand since they may originate from different sources. Hence, elucidating the role of Cl(-) as an independent player in blood pressure regulation will have clinical and public health implications in addition to advancing our understanding of electrolyte-mediated blood pressure regulation. In this review, we describe the evidence that support an independent role for Cl(-) on hypertension and cardiovascular health.
Maintenance fluid therapy and fluid creep impose more significant fluid, sodium, and chloride burdens than resuscitation fluids in critically ill patients: a retrospective study in a tertiary mixed ICU population
Intensive Care Med 2018 Apr;44(4):409-417.PMID:29589054DOI:10.1007/s00134-018-5147-3.
Purpose: Research on intravenous fluid therapy and its side effects, volume, sodium, and chloride overload, has focused almost exclusively on the resuscitation setting. We aimed to quantify all fluid sources in the ICU and assess fluid creep, the hidden and unintentional volume administered as a vehicle for medication or electrolytes. Methods: We precisely recorded the volume, sodium, and chloride burdens imposed by every fluid source administered to 14,654 patients during the cumulative 103,098 days they resided in our 45-bed tertiary ICU and simulated the impact of important strategic fluid choices on patients' chloride burdens. In septic patients, we assessed the impact of the different fluid sources on cumulative fluid balance, an established marker of morbidity. Results: Maintenance and replacement fluids accounted for 24.7% of the mean daily total fluid volume, thereby far exceeding resuscitation fluids (6.5%) and were the most important sources of sodium and chloride. Fluid creep represented a striking 32.6% of the mean daily total fluid volume [median 645 mL (IQR 308-1039 mL)]. chloride levels can be more effectively reduced by adopting a hypotonic maintenance strategy [a daily difference in chloride burden of 30.8 mmol (95% CI 30.5-31.1)] than a balanced resuscitation strategy [daily difference 3.0 mmol (95% CI 2.9-3.1)]. In septic patients, non-resuscitation fluids had a larger absolute impact on cumulative fluid balance than did resuscitation fluids. Conclusions: Inadvertent daily volume, sodium, and chloride loading should be avoided when prescribing maintenance fluids in view of the vast amounts of fluid creep. This is especially important when adopting an isotonic maintenance strategy.
Bench-to-bedside review: chloride in critical illness
Crit Care 2010;14(4):226.PMID:20663180DOI:10.1186/cc9052.
chloride is the principal anion in the extracellular fluid and is the second main contributor to plasma tonicity. Its concentration is frequently abnormal in intensive care unit patients, often as a consequence of fluid therapy. Yet chloride has received less attention than any other ion in the critical care literature. New insights into its physiological roles have emerged together with progress in understanding the structures and functions of chloride channels. In clinical practice, interest in a physicochemical approach to acid-base physiology has directed renewed attention to chloride as a major determinant of acid-base status. It has also indirectly helped to generate interest in other possible effects of disorders of chloraemia. The present review summarizes key aspects of chloride physiology, including its channels, as well as the clinical relevance of disorders of chloraemia. The paper also highlights current knowledge on the impact of different types of intravenous fluids on chloride concentration and the potential effects of such changes on organ physiology. Finally, the review examines the potential intensive care unit practice implications of a better understanding of chloride.
Geometric isomers of dichloridoiron(III) complexes of CTMC (5,7,12,14-tetramethyl-1,4,8,11-tetraazacyclotetradecane)
Acta Crystallogr C Struct Chem 2022 Sep 1;78(Pt 9):507-514.PMID:36063378DOI:10.1107/S205322962200849X.
Both trans and cis iron-CTMC complexes, namely, trans-dichlorido[(5SR,7RS,12RS,14SR)-5,7,12,14-tetramethyl-1,4,8,11-tetraazacyclotetradecane]iron(III) tetrachloridoferrate, [Fe(C14H32N4)Cl2][FeCl4] (1a), the analogous chloride methanol monosolvate, [Fe(C14H32N4)Cl2]Cl·CH3OH (1b), and cis-dichlorido[(5SR,7RS,12SR,14RS)-5,7,12,14-tetramethyl-1,4,8,11-tetraazacyclotetradecane]iron(III) chloride, [Fe(C14H32N4)Cl2]Cl (2), were successfully synthesized and structurally characterized using X-ray diffraction. The coordination geometry of the macrocycle is dependent on the stereoisomerism of CTMC. The packing of these complexes appears to be strongly influenced by extensive hydrogen-bonding interactions, which are in turn determined by the nature of the counter-anions (1a versus 1b) and/or the coordination geometry of the macrocycle (1a/1b versus 2). These observations are extended to related ferric cis- and trans-dichloro macrocyclic complexes.